EXCLUSIVE: Pharma's Cloud Revolution — A $60B Market By 2030 With 1 Stock To Watch
Benzinga
Published Mar 28, 2024 13:18
Updated Mar 28, 2024 14:40
EXCLUSIVE: Pharma's Cloud Revolution — A $60B Market By 2030 With 1 Stock To Watch
Benzinga - by Surbhi Jain, .
In an exclusive interview with Benzinga, Gregory DiMarzio, vice president and portfolio manager at Rockland Trust, shared insights on the current market landscape and highlighted potential growth opportunities for investors.
DiMarzio emphasized the health care sector’s underperformance year-to-date (YTD) and its potential for a rebound.
Healthcare Sector Offers Secular Growth Attributes/h2 Popular healthcare sector-tracking ETFs, the Health Care Select Sector SPDR ETF (NYSE:XLV) and the Vanguard Health Care ETF (NYSE:VHT) are up 6.4% and 6.2% YTD, respectively. The broad market SPDR S&P 500 ETF (NYSE:SPY) has gained 10.6% during that time. Over the past year, XLV and VHT have returned less than half of what the broad-market SPY has earned for investors.
Also Read: Beyond Tech And AI: Why The Sector Hedge Funds Prefer Is Not The One You’d Expect
Per DiMarzio, despite economic uncertainties, healthcare offers secular growth attributes that could position it well for the future. “Considering potential economic nervousness, the health care sector offers secular growth attributes that should help it rebound and either catch up with the overall market or be resistant to the downside should the market pull back,” he said.
Veeva Systems Has A Significant Opportunity For Growth, Says DiMarzio/h2 One stock within the healthcare sector that DiMarzio is bullish on is Veeva Systems Inc (NYSE:VEEV). Veeva Systems is a cloud-computing company specializing in pharmaceutical and life sciences applications.
DiMarzio highlighted, “Veeva Systems has a significant opportunity for growth because the industries it serves haven’t yet taken full advantage of utilizing cloud-based technology such as Veeva's.”
Veeva Systems’ innovative approach to cloud computing in pharmaceuticals and life sciences positions it as a leader in the industry, he said.
DiMarzio pointed out, “The total market size globally for cloud computing in pharmaceuticals is expected to reach nearly $60 billion by 2030, a 14.6% CAGR from 2022 – 2030.” This robust growth forecast underscores the vast potential for companies like Veeva Systems to capitalize on emerging trends in the health care sector.
Read Next: Did You Miss These 3 High-Yielding Dividend Stocks In Health Care Sector From Wall Street’s Most Accurate Analysts?
Image generated using artificial intelligence with Midjourney.
Latest Ratings for VEEV
| Mar 2022 | JMP Securities | Maintains | Market Outperform | |
| Mar 2022 | SVB Leerink | Maintains | Outperform | |
| Mar 2022 | B of A Securities | Downgrades | Buy | Neutral |
Get The App
View the Latest Analyst Ratings
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Read the original article on Benzinga
Written By: Benzinga
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.